EU's CHMP recommends Bial's anti-epileptic Zebinix
This article was originally published in Scrip
The EU's CHMP has recommended that a marketing authorisation be granted to Bial's Zebinix (eslicarbazepine acetate) for adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation. Zebinix will be available in 400mg, 600mg and 800mg tablets.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.